The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]
Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?
While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]
Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”, from which we get the following information: On the basis of the papers filed and the hearing session held, we find that these actions involve … [Read more...]
Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
Invokana (canagliflozin) was approved by the FDA in 2013. Invokamet (canagliflozin and metformin) was approved by the FDA in 2014. Both of these drugs were approved for use by patients with Type 2 diabetes. In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings … [Read more...]
Prevacid, Nexium, And Prilosec Linked To Risk Of Chronic Kidney Damage
A recent medical study done by medical researchers in St. Louis, Missouri indicates that more than half of those patients who develop chronic kidney damage (CKD) while using proton pump inhibitors (PPIs) heartburn drugs and acid reflux medicines do not experience acute kidney problems before their CKD diagnosis. These researchers published their … [Read more...]
December 2016: FDA Requires Safety Warnings Label Change For Jardiance
After the December 2, 2016 decision by the FDA decision by U.S. regulators to expand the health benefits for the relatively new diabetes medicine Jardiance (empagliflozin) to include preventing fatal heart attacks and strokes in type 2 diabetes patients, we saw news reports about its expected effect on Jardiance sales in the U.S. From this … [Read more...]
Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]
Nexium / Prevacid / Prilosec Series: The Devastating Side Effects
In the first article of the Nexium, Prevacid, Prilosec Series, I gave a brief overview of some of the possible side effects of these PPI drugs. I will now expand on this previous discussion to provide more detailed information about these conditions. Please know that I am not qualified to give medical advice, and am simply summarizing recent … [Read more...]
Nexium / Prevacid / Prilosec Series: Overview and Background
To start my series on Nexium, Prevacid, and Prilosec, I would like to provide some background information on these drugs, as well as a quick overview of their detrimental side-effects. For many years, popular heartburn and acid reflux drugs like Nexium, Prilosec, and Prevacid have been touted as safe by the drug manufacturers and doctors alike. … [Read more...]